PMID 39991130

Research
All papers

Affective valence predictors from real-world based short sprint interval training

Question

Which physiological responses predict affective valence after real-world short sprint interval training?

Summary

Seventeen healthy moderately active adults completed four very short sprint interval sessions using 10 x 4-second all-out running bouts. Participants reported positive post-session affect on average, completed all sessions, and the authors explicitly reported no fainting, respiratory events, nausea, dizziness, vomiting, or musculoskeletal injuries.

Methodology

  • Seventeen healthy moderately active Hispanic young adults
  • 17 participants.
  • All-out running.
  • Work intervals: 4 seconds.
  • Recovery: 30 seconds passive standing.
  • Intensity: All-out.
  • 8 min 10 s including warm-up.
  • Four sessions across two weeks.
  • 2 weeks.
  • Cross-sectional repeated-session observational exercise study
  • Affective valence, Perceived exertion, Heart-rate response, and Safety were tracked.

Outcomes

Affect

Average post-session affective valence was positive.

Feeling Scale 2.6 +/- 1.8.

Improved

Intensity

Sessions reached vigorous intensity.

77-93% HRpeak; mean HR 160.3 +/- 12.8 bpm.

Improved

Predictors

HR recovery, time >=90% HRpeak, and RMSSDend predicted affect.

F(3,61)=5.57, p=0.002, adjusted R2=0.177.

Mixed

Safety

No adverse symptoms or injuries were reported.

No clear change

Insights

  • Very short all-out sprint bouts may produce positive affect in already active adults.
  • Affect and recovery markers can be useful personalization signals.
  • The total all-out work dose was only 40 seconds per session.

Limitations

  • Small sample.
  • Participants were moderately active, not inactive or clinical.
  • Menstrual cycle was not controlled.
  • Affect was measured immediately after exercise only.
  • No lactate measurement and no long-term adherence outcomes.

Safety

  • All 17 participants completed all four sessions.
  • The authors explicitly reported no fainting, respiratory events, nausea, dizziness, vomiting, or musculoskeletal injuries.
  • Participants were screened to exclude cardiometabolic risk, musculoskeletal injury, pregnancy/lactation, supplements, drugs, and tobacco use.